Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2018

Study Completion Date

February 29, 2020

Conditions
Thymoma and Thymic Carcinoma
Interventions
RADIATION

concurrent chemoradiation

The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w\*4.

Trial Locations (1)

20032

Kailiang Wu, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT02636556 - Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors | Biotech Hunter | Biotech Hunter